SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 177 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $34,088,211 | -35.4% | 2,347,673 | -6.9% | 0.03% | -32.6% |
| Q2 2023 | $52,783,704 | +3.4% | 2,521,916 | +4.4% | 0.04% | -8.5% |
| Q1 2023 | $51,035,510 | -12.9% | 2,416,454 | +5.0% | 0.05% | -20.3% |
| Q4 2022 | $58,592,163 | +47.8% | 2,302,246 | +39.5% | 0.06% | +51.3% |
| Q3 2022 | $39,645,000 | +752.2% | 1,649,795 | +210.7% | 0.04% | +680.0% |
| Q4 2017 | $4,652,000 | -58.2% | 531,028 | -44.2% | 0.01% | -54.5% |
| Q3 2017 | $11,137,000 | -16.4% | 951,898 | -0.2% | 0.01% | -21.4% |
| Q2 2017 | $13,325,000 | +1882.9% | 953,862 | +917.1% | 0.01% | +1300.0% |
| Q4 2016 | $672,000 | -88.4% | 93,783 | -75.6% | 0.00% | -83.3% |
| Q3 2016 | $5,818,000 | +10.9% | 383,776 | -28.6% | 0.01% | 0.0% |
| Q2 2016 | $5,247,000 | -12.2% | 537,545 | +16.6% | 0.01% | 0.0% |
| Q1 2016 | $5,978,000 | – | 460,892 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |